BridgeBio Pharma announced that preliminary data on the Company’s muscle tissue-based bioassay measuring glycosylated aDG in LGMD2I patients will be featured in an oral presentation and posters at the MDA 2023 Annual Meeting, taking place in Dallas, Texas on March 19 – 22, 2023. BridgeBio was selected to share an oral presentation and posters on its ongoing Phase 2 trial with 15-month results, including the preliminary design of its pivotal Phase 3 study in patients with LGMD2I, which is expected to launch in mid-2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)
- BridgeBio 8.824M share Secondary priced at $17.00
- Ascendis Pharma has positive read-through from BridgeBio data, says BofA
- 3 Stocks to Buy Today, 3/7/2023, According to Top Analysts
- Tyra Biosciences has positive read-through from BridgeBio data, says BofA